e-mail submissions to correspondence@lancet.com
Sir—Björn Dahlöf, in the LIFE study,1
Lars Lindholm and colleagues “to share exciting news” and remind
me of the results of the LIFE study.
cardiologists received the same letter. I
porosity of liver sinusoids in relation to
loss of integrity of the endothelial lining,
Dahlöf B, Devereux RB, Kjeldsen SE, et al.
Cardiovascular morbidity and mortality in
reduction in hypertension study (LIFE): a
randomised trial against atenolol. Lancet
2002; 359: 995–1003.
into the analysis of the trial results is
Department of Clinical Epidemiology, Leiden
The Lancet entirely on its scientific
Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in
(1·5–1·9 vs 15–25 fenestrae/µm2).
reduction in hypertension study (LIFE): a
randomised trial against atenolol. Lancet
2002; 359: 995–1003.
Lindholm LH, Ibsen H, Dahlöf B, et al.
Cardiovascular morbidity and mortality in
hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:
THE LANCET • Vol 360 • October 12, 2002 • www.thelancet.com
For personal use. Only reproduce with permission from The Lancet Publishing Group.
Department of Infectious Diseases and Tissue
Typing Laboratory, Department of Clinical
Roy S, Knox K, Segal S, et al. MBL
outside5 the Cleveland Clinic cohorts.
study. Lancet 2002; 359: 1569–73.
Garred P, Madsen HO, Halberg P, et al.
and susceptibility to infection in systemic
lupus erythematosus. Arthritis Rheum 1999;
42: 2145–52.
Kronborg G, Weis N, Madsen HO, et al.
Variant mannose-binding lectin alleles are
not associated with susceptibility to and
infection in randomly included patients.
J Infect Dis 2002; 185: 1517–20.
Garred P, Pressler T, Madsen HO, et al.
Association of mannose-binding lectin gene
heterogeneity with severity of lung disease
and survival in cystic fibrosis. J Clin Invest
1999; 104: 431–37.
Koch A, Melbye M, Sorensen P, et al.
risk (nine [6·4%] of 140 vs seven
during early childhood. JAMA 2001; 285:
significant, we took no further notice.
the relevant issue in heart-rate recovery
significant (p<0·0001) increased risk
athletes, and heart-failure patients.
biologically based hypothesis. Its ability
MSL receives research support from theNational Heart, Lung, and Blood Institute of
*Michael S Lauer, Victor Froelicher
*Clinical Research and Stress Laboratory,
Department of Cardiovascular Medicine, DeskF25, Cleveland Clinic Foundation, 9500 Euclid
Division of Cardiovascular Medicine, StanfordUniversity Medical Center and the Veterans
A=normal MBL allele; O=common designation for variant alleles B (codon 54), C (codon 57), D (codon 52).
Affairs Palo Alto Health Care System, Palo Alto,
*Initial patient set. †Confirmatory study.
Combined analysis of three MBL association studies
THE LANCET • Vol 360 • October 12, 2002 • www.thelancet.com
For personal use. Only reproduce with permission from The Lancet Publishing Group.
recovery after exercise. Lancet 2002; 359:
mediated heart rate recovery after exercise isaccelerated in athletes but blunted in
patients with chronic heart failure. J Am CollCardiol 1994; 24: 1529–35.
Snader CE, Lauer MS. Heart-rate recoveryimmediately after exercise as a predictor of
mortality. N Engl J Med 1999; 341:
Pashkow FJ, Lauer MS. Heart rate recovery
and treadmill exercise score as predictors ofmortality in patients referred for exercise
ECG. JAMA 2000; 284: 1392–98.
Shetler K, Marcus R, Froelicher VF, et al.
mineral riches. It is set to produce 2·5
methodologic issues. J Am Coll Cardiol 2001; 38: 1980–87.
right to explore untapped oil reservesprovide nearly US$1 billion, but
Our research was partly funded by the Secure
the Future Project of Bristol-Myers Squibb.
much of that is used to finance thewar effort. In the past decade, more
Centre for Actuarial Research, and School of
Public Health, University of Cape Town, South
Africa; *Burden of Disease Research Unit,
and Biostatistics Unit, South African Medical
Research Council, PO Box 19070, Tygerberg
7505, South Africa; and Centre for Population
registrations. It does no such thing.
Fiala C, de Harven E, Herxheimer A, et al.
HIV/AIDS data in South Africa. Lancet
2002; 359: 1782.
1997–2000. Statistical release P0309.1.
Pretoria: Statistics South Africa, 2001.
available for years later than 1996.
http://www.gov.za/speeches/cabinetaids02.
mortality statistics for 1997–2000.3 In
that statistics report’s introduction, it
THE LANCET • Vol 360 • October 12, 2002 • www.thelancet.com
For personal use. Only reproduce with permission from The Lancet Publishing Group.
Solution Oriented Hypnotic Analgesia in Naltrexone Treatment for Heroin Addiction Abstract I have been using Solution Oriented Hypnosis and Solution Oriented Counselling for anumber of years. During that time, I have counselled several hundred Heroin addicts whowere undergoing Rapid Opiate Detoxification (ROD) with the drug Naltrexone. Heroinaddicts suffer from acute and chronic pain. Nal
Änderungen im Erstattungskodex (EKO) ab Dezember 2010 Informationsstand Dezember 2010 ROT → GRÜN Aufnahme kostengünstiger Nachfolgepräparate in den Grünen Bereich: Präparat Menge T OP KVP € Kostenersparnis € pro Packung* A02 MITTEL BEI SÄURE BEDINGTEN ERKRANKUNGEN A02BC02 Pantoprazol Pantoprazol “ratiopharm“ 20 mg magensaftresistente Tabl